AstraZeneca, BMS regroup with promising dapagliflozin PhIII diabetes data

Two years after AstraZeneca and Bristol-Myers Squibb ran into a buzzsaw of regulatory criticism at the FDA for their SGLT2 diabetes drug dapagliflozin, the partners are back with a fresh set of promis…
Read the full story: FierceBiotech News